Elanco Animal Health Incorporated (NYSE:ELAN) Short Interest Update

Elanco Animal Health Incorporated (NYSE:ELAN) saw a large decline in short interest in February. As of February 13th, there was short interest totaling 18,414,142 shares, a decline of 20.7% from the January 29th total of 23,228,810 shares. Based on an average daily volume of 4,571,050 shares, the short-interest ratio is presently 4.0 days. Currently, 3.7% of the shares of the stock are sold short. Currently, 3.7% of the shares of the stock are sold short. Based on an average daily volume of 4,571,050 shares, the short-interest ratio is presently 4.0 days.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 22,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was acquired at an average cost of $21.75 per share, with a total value of $478,500.00. Following the completion of the acquisition, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. This represents a 15.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. This represents a 5.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 43,450 shares of company stock worth $937,883 in the last quarter. 0.89% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC raised its holdings in shares of Elanco Animal Health by 5.9% during the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the period. Lazard Asset Management LLC increased its holdings in Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after purchasing an additional 425 shares in the last quarter. Northwestern Mutual Investment Management Company LLC raised its stake in shares of Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after purchasing an additional 428 shares during the period. Meeder Advisory Services Inc. raised its position in Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after buying an additional 510 shares during the last quarter. Finally, Root Financial Partners LLC raised its position in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 0.6%

Shares of NYSE ELAN opened at $26.35 on Monday. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $27.72. The stock has a market cap of $13.10 billion, a price-to-earnings ratio of -54.90, a P/E/G ratio of 3.38 and a beta of 1.83. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. The company’s fifty day moving average is $24.23 and its 200-day moving average is $21.81.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter last year, the business posted $0.14 EPS. The firm’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities research analysts predict that Elanco Animal Health will post 0.91 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Wednesday, November 19th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. UBS Group upped their target price on shares of Elanco Animal Health from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. JPMorgan Chase & Co. increased their price target on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Finally, Leerink Partners lifted their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $27.67.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.